152 related articles for article (PubMed ID: 35616366)
1. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma.
Guo Y; Peng Q; Hao L; Ji J; Zhang Z; Xue Y; Liu Y; Gao Y; Li C; Shi X
FASEB J; 2022 Jun; 36(6):e22361. PubMed ID: 35616366
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin inhibited interleukin-18 expression by decreasing YAP1 in hepatocellular carcinoma cells.
Gong Y; Peng Q; Gao Y; Yang J; Lu J; Zhang Y; Yang Y; Liang H; Yue Y; Shi X
Acta Histochem; 2023 May; 125(4):152040. PubMed ID: 37119608
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8
Gao Y; Gong Y; Lu J; Yang Y; Zhang Y; Xiong Y; Shi X
Biochem Pharmacol; 2024 Jul; 225():116294. PubMed ID: 38754557
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma.
Hao L; Guo Y; Peng Q; Zhang Z; Ji J; Liu Y; Xue Y; Li C; Zheng K; Shi X
Phytomedicine; 2022 Feb; 96():153913. PubMed ID: 35026515
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.
Peng Q; Hao L; Guo Y; Zhang Z; Ji J; Xue Y; Liu Y; Li C; Lu J; Shi X
J Nat Med; 2023 Jan; 77(1):28-40. PubMed ID: 36068393
[TBL] [Abstract][Full Text] [Related]
6. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.
Chen Y; Song X; Valanejad L; Vasilenko A; More V; Qiu X; Chen W; Lai Y; Slitt A; Stoner M; Yan B; Deng R
Hepatology; 2013 Apr; 57(4):1530-41. PubMed ID: 23213087
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy.
Zhang Z; Shi X; Ji J; Guo Y; Peng Q; Hao L; Xue Y; Liu Y; Li C; Lu J; Yu K
Front Med; 2023 Aug; 17(4):729-746. PubMed ID: 37121958
[TBL] [Abstract][Full Text] [Related]
8. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
9. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis.
Li T; Matozel M; Boehme S; Kong B; Nilsson LM; Guo G; Ellis E; Chiang JY
Hepatology; 2011 Mar; 53(3):996-1006. PubMed ID: 21319191
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
[TBL] [Abstract][Full Text] [Related]
12. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
[TBL] [Abstract][Full Text] [Related]
14. Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosis.
Fu Y; Feng H; Ding X; Meng QH; Zhang SR; Li J; Chao Y; Ji TT; Bi YH; Zhang WW; Chen Q; Zhang YH; Feng YL; Bian HM
Phytomedicine; 2022 Jul; 101():154120. PubMed ID: 35523117
[TBL] [Abstract][Full Text] [Related]
15. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein.
Kok T; Hulzebos CV; Wolters H; Havinga R; Agellon LB; Stellaard F; Shan B; Schwarz M; Kuipers F
J Biol Chem; 2003 Oct; 278(43):41930-7. PubMed ID: 12917447
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids.
Chen W; Owsley E; Yang Y; Stroup D; Chiang JY
J Lipid Res; 2001 Sep; 42(9):1402-12. PubMed ID: 11518759
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
Kim I; Ahn SH; Inagaki T; Choi M; Ito S; Guo GL; Kliewer SA; Gonzalez FJ
J Lipid Res; 2007 Dec; 48(12):2664-72. PubMed ID: 17720959
[TBL] [Abstract][Full Text] [Related]
18. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
19. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits.
Xu G; Li H; Pan LX; Shang Q; Honda A; Ananthanarayanan M; Erickson SK; Shneider BL; Shefer S; Bollineni J; Forman BM; Matsuzaki Y; Suchy FJ; Tint GS; Salen G
J Lipid Res; 2003 Oct; 44(10):1956-62. PubMed ID: 12897188
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
